AWHL Aspira Women's Health Inc.
Debt Financing ·
Aspira Women's Health signed a $1,050,000 secured subordinated note with Agile Lending, LLC as lead lender. The note matures January 26, 2027, and the company will use it to refinance an earlier January loan.
Chairman John Fraser takes over as interim chief executive effective June 17, 2026, while the board searches for a permanent CEO. Terms of Michael Buhle's separation agreement are not yet final.
The June 5, 2026 deal sold 3,300,000 shares at $0.45 each, with warrants to buy up to 4,455,000 more shares. The filing names no underwriter or placement agent.
The master collaboration and license agreement covers biomarker discovery, validation and analytical models for women's health diagnostics. The release states no financial terms.
John Strahley joins as a fractional CFO and chief accounting officer effective April 27, 2026, on a $167,000 base salary, after the consulting arrangement with Brian Hungerford ended.
Aspira says it needs more time to finish accounting for debt and equity deals from the first quarter, and it expects a smaller net loss helped by a milestone payment.
Nasdaq's hearings panel has decided to delist Aspira Women's Health, which says its shares will trade on OTC markets under the symbol AWH.
Aspira Women's Health Inc. is dedicated to the discovery, development and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. It plans to broaden its focus to the differential diagnosis of other gynecologic diseases that typically cannot be assessed through traditional noninvasive clinical procedures. Its commercial OvaWatch test monitors adnexal masses through periodic testing at physician prescribed intervals. The OVAinform program is a multi-marker test that combines serum proteins, microRNA and clinical data to assess ovarian cancer risk. Its endometriosis program, ENDOinform, is a multi-marker test designed to aid the identification of endometriosis, which the text says affects approximately 10% of reproductive age women. The company owns and operates Aspira Labs, Inc., a CLIA certified laboratory in Texas. A contract from the Advanced Research Projects Agency for Health for ENDOinform was terminated in June 2025 after the company did not meet the specifications of the third milestone. The company says its current capital resources are not sufficient to fund its operations for the remainder of 2026. Its common stock began trading on the OTC Markets in April 2025 and is quoted on the OTC QX Best Market.
| Product or program | What it is | Stage |
|---|---|---|
| OvaWatch | Monitors adnexal masses through periodic testing at physician prescribed intervals | Commercially available |
| OVAinform | Multi-marker test combining proteins, miRNA and clinical data for ovarian cancer risk | Development program continues to progress |
| ENDOinform | Multi-marker test combining serum proteins, miRNA and metadata to identify endometriosis | In development |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $343,000 | $4,000 |
| Research and development | $2.9 million | $3.3 million |
| Net income (loss) | -$12.8 million | -$13.1 million |
| Cash from operations | -$7.0 million | -$12.1 million |
| Cash and equivalents | $1.8 million | $1.8 million |
Our latest story on this, dated Apr 16, 2025: "Nasdaq panel delists Aspira Women's Health over $2.5 million equity rule". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 5, 2026: "Aspira Women's Health closes $1.485 million private placement". The story links the filing or release it is based on. Read the story.
Aspira Women's Health Inc. trades under the ticker AWHL on OTC.
Aspira Women's Health Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Aspira Women's Health Inc. is 926617. Its filings are on SEC EDGAR.
46,633,744 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Aspira Women's Health Inc. under United States.
Our directory classifies Aspira Women's Health Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Aspira Women's Health Inc. is US04537Y2081.
aibio.space lists Aspira Women's Health Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Aspira Women's Health Inc. is dedicated to the discovery, development and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. It plans to broaden its focus to the differential diagnosis of other gynecologic diseases that typically cannot be assessed through traditional noninvasive clinical procedures.
OvaWatch: Monitors adnexal masses through periodic testing at physician prescribed intervals Stage: Commercially available.
OVAinform: Multi-marker test combining proteins, miRNA and clinical data for ovarian cancer risk Stage: Development program continues to progress.
$343,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio